Despite recent major therapeutic advances in multiple myeloma, refractory disease relapse/progression, especially after auto-SCT, remains an unmet challenge in the field. Genetically, frequent RAS mutation has been reported in myeloma.
/D1 and D4, sorafenib 200 mg b.i.d., dexamethasone 20 mg D1-D4 and D8-D11) with non-durable response, during which his IgG dropped from 7180 mg/dL to a nadir of 6340 mg/dL briefly ( Figure 1 ). Despite further salvage with PAD (bortezomib 1.3 mg/m 2 /day D1, D4, D8 and D11, doxorubicin 9 mg/m 2 D1-D4, dexamethasone 20 mg/day D1-D4 and D8-D11), serum IgG escalated to 9100 mg/dL, when he was started on VBD (bortezomib 1.3 mg/m 2 /day D1 and D4, bendamustine 90 mg/m 2 /day D1 and D4, and dexamethasone 20 mg/day D1-D4), every 4 weeks. He achieved a PR after eight cycles of VBD with the latest serum IgG of 1820 mg/dL (Figure 1 ). This patient had proven refractory to both bortezomib and lenalidomide even during induction. Despite achieving a very good PR after auto-SCT, his disease progressed 9 months post auto-SCT, suggestive of highly refractory myeloma, which was evidenced by the aggressive disease progression with rapidly rising IgG levels. Moreover, as his disease progressed within 9 months after auto-SCT, hence myeloma cells were likely chemorefractory to high-dose melphalan in addition to bortezomib, thalidomide and lenalidomide. Unfortunately, carfilzomib and pomalidomide were not available. Therefore, novel therapies instead of conventional chemotherapy were considered at relapse.
Interestingly, his BM plasma cells at refractory relapse showed ERK1/2 activation in western blotting analysis. Despite that RAS mutation occurs in 420% in myeloma, 1 few cases have been demonstrated to be associated with RAS activation by functional assay such as western blotting of phosphorylated ERK. Moreover, in contrast to conventional belief that ERK activation in myeloma is often caused by gain-of-function RAS mutation or RASSF1A methylation, 1, 8 our case showed activating BRAF kinase V600E mutation instead, which has been shown to occur in about 2% of myeloma cases. 9 BRAF is a serine-threonine kinase, and a component of the RAS-RAF-MEK-ERK signaling pathway, which transmits mitogenic signals from activated cell surface growth factor receptors. Furthermore, RAS and RAF mutations are almost mutually exclusive in myeloma. 2, 9 Therefore, this V600E gain-offunction BRAF mutation renders RAS-independent activation of ERK. K601N (lysine (K) to an asparagine (N)), V600E (valine (V) to a glutamate (E)) and G469A (glycine (G) to an alanine (A)) mutation account for all BRAF mutations that have previously been described in myeloma. 9 In this connection, sorafenib, a multikinase inhibitor that blocks both BRAF and CRAF kinase, has been shown to be effective in cancers with BRAF mutation. 10 Moreover, sorafenib has been shown in vitro to be sygnergistic with bortezomib, 3 hence the bortezomib-sorafenib combination has been used here with non-durable response, possibly due to a more potent inhibition of CRAF than BRAF by sorafenib. 10 Unfortunately, the V600E-specific BRAF inhibitor vemurafenib is not available.
11
Bendamustine is a chemical hybrid of nitrogen mustard and benzimidazole, hence possessing properties of both alkylator and purine analogue. Bendamustine is non-cross resistant to other chemotherapies, and effective in indolent non-Hodgkin's lymphoma, CLL and myeloma. 12 We have previously shown that bortezomib could restore chemosensitivity in myeloma patient refractory to multiple chemotherapeutic agents, 4 hence employed VBD in this patient with rapidly progressive relapse with bortezomib-based therapy. Consistent with its non-cross resistance to other alkylating agents, he achieved good PR to this bendamustine combination. Indeed, recent studies of bendamustine/prednisolone in relapsed/refractory myeloma showed a modest response rate, 13 but much higher rate of response (60%) is achieved by combining bortezomib with bendamustine and dexamethasone.
14 Finally, the rationale for the use of bortezomib even in patients refractory to bortezomib is based on in vitro and in vivo data showing restoration of chemosensitivity of alkylating agents in chemoresistant myeloma cells. 4 Functionally validated activation of RAS-RAF-MEK-ERK signaling may be associated with BRAF V600E mutation instead of KRAS/NRAS mutation or RASSF1A hypermethylation. Sorafenib is not potent enough to induce a significant response in this case of RAS activation due to BRAF mutation, hence warrants a trial of vemurafenib. VBD is an active regimen even in myeloma patients , and t(14;16) showed the presence of amp(1q21) only. Sequencing of NRAS, KRAS, and BRAF showed V600E BRAF mutation. Methylation-specific PCR indicated unmethylation of RASSF1A promoter (UU). Western blot analysis of CD138-sorted BM plasma cells showed ERK1/2 activation. +++, positive for phospho-ERK1/2; UU, unmethylation; WT, wild type. HeLa and KMS-12-BM cells served as positive and negative controls for ERK activation, respectively.
